Cellectar to Present Three Iopofosine Posters at ASH Meeting

Updated Phase 2b analyses show durable responses in heavily pretreated patients. Cellectar will also present a Phase 3 trial-in-progress design; first-patient dosing remains on track for 1Q 2027.